» Articles » PMID: 20146558

A Systematic Review of Non-invasive Pharmacologic Neuroprotective Treatments for Acute Spinal Cord Injury

Overview
Journal J Neurotrauma
Publisher Mary Ann Liebert
Date 2010 Feb 12
PMID 20146558
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

An increasing number of therapies for spinal cord injury (SCI) are emerging from the laboratory and seeking translation into human clinical trials. Many of these are administered as soon as possible after injury with the hope of attenuating secondary damage and maximizing the extent of spared neurologic tissue. In this article, we systematically review the available pre-clinical research on such neuroprotective therapies that are administered in a non-invasive manner for acute SCI. Specifically, we review treatments that have a relatively high potential for translation due to the fact that they are already used in human clinical applications, or are available in a form that could be administered to humans. These include: erythropoietin, NSAIDs, anti-CD11d antibodies, minocycline, progesterone, estrogen, magnesium, riluzole, polyethylene glycol, atorvastatin, inosine, and pioglitazone. The literature was systematically reviewed to examine studies in which an in-vivo animal model was utilized to assess the efficacy of the therapy in a traumatic SCI paradigm. Using these criteria, 122 studies were identified and reviewed in detail. Wide variations exist in the animal species, injury models, and experimental designs reported in the pre-clinical literature on the therapies reviewed. The review highlights the extent of investigation that has occurred in these specific therapies, and points out gaps in our knowledge that would be potentially valuable prior to human translation.

Citing Articles

Novel carbon dots with dual Modulatory effects on the bone marrow and spleen as a potential therapeutic candidate for treating spinal cord injury.

Li J, Wang H, Li Y, Wang C, Feng H, Pang Y Bioact Mater. 2025; 45:534-550.

PMID: 39759534 PMC: 11696655. DOI: 10.1016/j.bioactmat.2024.11.032.


Differential effects of exercise and hormone treatment on spinal cord injury-induced changes in micturition and morphology of external urethral sphincter motoneurons.

Hibbard E, Du X, Zhang Y, Xu X, Deng L, Sengelaub D Restor Neurol Neurosci. 2024; 42(2):151-165.

PMID: 39213108 PMC: 11851999. DOI: 10.3233/RNN-241385.


Administration of Tamoxifen Can Regulate Changes in Gene Expression during the Acute Phase of Traumatic Spinal Cord Injury.

Cabrera-Aldana E, Balderas-Martinez Y, Velazquez-Cruz R, Tovar-y-Romo L, Sevilla-Montoya R, Martinez-Cruz A Curr Issues Mol Biol. 2023; 45(9):7476-7491.

PMID: 37754256 PMC: 10529143. DOI: 10.3390/cimb45090472.


Advances in molecular therapies for targeting pathophysiology in spinal cord injury.

Kim H, McCrea M, Li S Expert Opin Ther Targets. 2023; 27(3):171-187.

PMID: 37017093 PMC: 10148912. DOI: 10.1080/14728222.2023.2194532.


Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis.

Panizzutti B, Skvarc D, Lin S, Croce S, Meehan A, Bortolasci C Int J Mol Sci. 2023; 24(6).

PMID: 36982324 PMC: 10049047. DOI: 10.3390/ijms24065250.


References
1.
Resnick D, Graham S, Dixon C, Marion D . Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma. 1999; 15(12):1005-13. DOI: 10.1089/neu.1998.15.1005. View

2.
Martinez-Arizala A, Green B . Hypothermia in spinal cord injury. J Neurotrauma. 1992; 9 Suppl 2:S497-505. View

3.
Gok B, Okutan O, Beskonakli E, Kilinc K . Effects of magnesium sulphate following spinal cord injury in rats. Chin J Physiol. 2007; 50(2):93-7. View

4.
Stirling D, Khodarahmi K, Liu J, McPhail L, McBride C, Steeves J . Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci. 2004; 24(9):2182-90. PMC: 6730425. DOI: 10.1523/JNEUROSCI.5275-03.2004. View

5.
Park S, Yi J, Miranpuri G, Satriotomo I, Bowen K, Resnick D . Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther. 2006; 320(3):1002-12. DOI: 10.1124/jpet.106.113472. View